ViperaTAb™ is available in Europe on a named patient basis. ViperaTAb™, a Polyvalent Immune Fab (Ovine), comprises specific antibody fragments that bind and neutralise Vipera berus venom components, including proteases, lipases and cardiotoxins, facilitating their redistribution away from target tissues and subsequent elimination from the body.
ViperaTAb™ is an antidote for the treatment of snakebites by the European common adder (Vipera berus), offering a treatment for the 750 bites which occur each year in Europe*. This product is currently available on a named patient basis in Sweden, Finland, Norway, Denmark, Iceland, Estonia, Latvia, Lithuania and Germany under an agreement with Swedish Orphan Biovitrum International AB (www.sobi.com), and in other territories from Flynn Pharma Limited (www.flynnpharma.com).
Affinity Purified, European Viper Antivenom (Ovine Fab for Injection)
European common adder (Vipera berus) envenomation